1988
DOI: 10.1177/000456328802500201
|View full text |Cite
|
Sign up to set email alerts
|

Audit of Therapeutic Drug Monitoring

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
4
0

Year Published

1990
1990
2019
2019

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 33 publications
0
4
0
Order By: Relevance
“…Other conditions in which TDM may be especially rewarding include the check for compliance and the management of patients in whom AED pharmacokinetics is likely to be altered by developmental factors, associated disease, or drug interactions. The setting of precise indications for TDM is important in view of the evidence that serum drug levels are often requested inappropriately (6,12,13,18). Misinterpretation of the results (for example, increasing dos-age despite evidence that a patient is well controlled at a level below the usually quoted optimal range) also seems to be a common problem leading to potentially harmful clinical decisions (14)(15)(16).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Other conditions in which TDM may be especially rewarding include the check for compliance and the management of patients in whom AED pharmacokinetics is likely to be altered by developmental factors, associated disease, or drug interactions. The setting of precise indications for TDM is important in view of the evidence that serum drug levels are often requested inappropriately (6,12,13,18). Misinterpretation of the results (for example, increasing dos-age despite evidence that a patient is well controlled at a level below the usually quoted optimal range) also seems to be a common problem leading to potentially harmful clinical decisions (14)(15)(16).…”
Section: Discussionmentioning
confidence: 99%
“…In epilepsy, the wave of overenthusiasm for TDM subsided many years ago (6), partly because of the observation that there is considerable variation in the serum level at which individual patients achieve optimal re-sponses (7-1 1), and the realization that inadequate use of the service may result in unacceptable waste of resources (6,12,13) and even harm to patients' health (14)(15)(16). Even though precise criteria for the optimal use of TDM have been formulated (8,9,11,(17)(18)(19)(20) and the usefulness of a correctly applied service has been suggested on the basis of retrospective surveys (21,22), there has been a paucity of studies in which the impact of serum AED determinations has been evaluated prospectively (1 1,23, 24).…”
mentioning
confidence: 99%
“…Based on the understanding that incorrect use of a service (e.g., TDM) may result in intolerable waste of funds 5,19,20 and even harm to patient health, 21 23 the study aims to assess the practices associated with the application of TDM services for AEDs in the management of children with structural–metabolic epilepsy.…”
Section: Introductionmentioning
confidence: 99%
“…Hence, a good understanding of the physiological processes as well as the pharmacokinetics (PK) [what the body does to the drug] and pharmacodynamics (PD) [what the drug does to the body]) of the drugs is necessary to appreciate the differences, so that this knowledge can be utilised in the decision-making processes regarding the choice of OAC [3,4]. Hence, this review article aims to provide a detailed review of these characteristics of the commonly used VKAs (warfarin (Coumadin®), phenprocoumon (Marcoumar®) and acenocoumarol (Sinthrome®)) as well as NOACs (dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and edoxaban (Lixiana®) .…”
mentioning
confidence: 99%